16results about How to "Reduce the ability to invade" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of umbilical cord mesenchymal stem cells and monoclonal antibodies in combined treatment of cancers. The monoclonal antibody is a monoclonal antibody specifically aiming at human PAFAH1B3 protein, the amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO: 1, and the amino acid sequence of a light chain variable region of the monoclonal antibody is as shown in SEQ ID NO: 2. The PAFAH1B3 protein monoclonal antibody can significantly inhibit the proliferation capacity of pancreatic cancer cells, and after the umbilical cord mesenchymal stem cells and the PAFAH1B3 protein monoclonal antibody are combined for use, the inhibition effect on the proliferation capacity of the pancreatic cancer cells is better, and the umbilical cord mesenchymal stem cells can be used for preparing anti-cancer drugs and have good application prospects.

The invention discloses a traditional Chinese medicine composition for treating triple-negative breast cancer pulmonary metastasis, which is prepared from the following raw material medicines in parts by weight: 3-5 parts of herba epimedii, 3-5 parts of pseudobulbus cremastrae seu pleiones, 5-15 parts of rhizoma curcumae, 2-8 parts of nidus vespae and 5-15 parts of fructus akebiae. The traditional Chinese medicine composition disclosed by the invention has the effects of removing blood stasis and removing stasis, soothing liver and regulating qi, tonifying kidney and strengthening bone, and removing stasis and detoxifying, and can improve the disease-free survival rate of a metastatic breast cancer patient after operation for 2 years, delay the recurrence and metastasis of the postoperative breast cancer, enhance the immunity of the patient and improve the clinical symptoms of the patient. In addition, the invention further discloses a preparation method and application of the traditional Chinese medicine composition.

The invention provides a gene knockout method of micromonas microflora and application of the gene knockout method. The method comprises the following steps: firstly, obtaining an upstream homologous arm fragment and a downstream homologous arm fragment of a gene tmpc to be knocked out, and an ermB resistance gene fragment; connecting the three fragments to obtain a fused DNA fragment; and finally, gene knockout of the micromonas minuta is realized by adopting a natural transformation method. According to the invention, the problem that the micromonas minuta is difficult to transform and edit genes is effectively solved. And the provided micromonas tautomonas of which the gene tmpc is knocked out can be used for researching the mechanism that the micromonas tautomonas is attached to and invades the OSCC cells. According to the present invention, it is verified that the TmpC is the necessary effector of P.micra for promoting OSCC transfer in vivo through the micromonas sp of which the gene tmpc is knocked out, and the adhesion and invasion ability of the P.micra to OSCC cells in vitro is significantly reduced;

The invention discloses an application of osmundone in preparation of a medicine for treating methicillin-resistant staphylococcus aureus infectious pneumonia. Experimental results of an MRSA mouse pneumonia infection model show that osmundone can significantly reduce the bacterial load in lung tissues, alleviate excessive inflammatory response caused by infection and effectively improve the survival rate of mice. In addition, the invention discloses that osmundone reduces the adhesion and invasion ability of bacteria, reduces the toxicity of the bacteria and plays an antibacterial role by inhibiting the protein activity of staphylococcus aureus Sortase A (SrtA). Different from traditional antibiotics, osmundone does not apply survival pressure to bacteria, so that generation of drug resistance is not easily induced. On the basis, osmundone shows a good application prospect in the aspect of research and development of safe and effective MRSA infectious pneumonia treatment drugs.

The invention discloses an application of isoliensinine in preparation of a medicine for treating staphylococcus aureus infectious arthritis. According to a treatment model of SD rat staphylococcus aureus infectious arthritis, the isoliensinine is proved to be capable of improving excessive inflammatory response of joint tissues infected by staphylococcus aureus and remarkably relieving pathological injury of rat joints, and the isoliensinine has a relatively good treatment effect on staphylococcus aureus infectious arthritis. In addition, the invention reveals that the isoliensinine is combined with a staphylococcus aureus reaction regulatory factor SaeR in a targeted manner, so that the toxicity of staphylococcus aureus is reduced to play a role. Compared with the traditional antibiotic for treating staphylococcus aureus, the isoliensinine has the advantages of no survival pressure on germs and no generation of drug resistance of the germs. Therefore, the isoliensinine has a relatively good potential application prospect in research and development of safe and effective medicines for treating the staphylococcus aureus infectious arthritis.

This invention provides bfrA Single gene knockout or bfrA Genes and bfrB Double gene knockout of Neisseria gonorrhoeae and its applications involve the field of biotechnology. Research has found that... bfrA Single gene knockout and bfrA and bfrB Double gene knockout of Neisseria gonorrhoeae resulted in increased formation of vesicles on the outer membrane, disruption of the cell wall and cell membrane, reduced adhesion and invasion abilities, decreased bacterial activity, decreased ATP levels, and weakened ability to infect mice. Therefore, knocking out Neisseria gonorrhoeae... bfrA Gene or bfrA and bfrB The dual-gene assay can be used to prepare products for the production of gonococcal outer membrane vesicles and to construct low-pathogenic gonococcal models.

The present invention relates to biomedicine, and in particular to LncRNA WARS2-IT1 inhibitors and applications thereof. After knocking down or silencing LncRNA WARS2-IT1 using the LncRNA WARS2-IT1 inhibitor, the proliferation ability, migration ability, and invasion ability of glioma cells are significantly reduced. The LncRNA WARS2-IT1 inhibitor can be used in the preparation of products such as diagnosis and treatment of gliomas and improving the sensitivity of targeted drugs, and has good application prospects.

The present application relates to the application of cereal bran oligopeptide in the preparation of drugs and / or products for preventing and / or treating colorectal cancer metastasis, and belongs to the technical field of medical uses. The amino acid sequence of the cereal bran oligopeptide is shown in SEQ ID NO. 1 or SEQ ID NO. 2. The cereal bran oligopeptide can target and antagonize the activation of integrin alpha v beta 6 and alpha v beta 3 subtypes, effectively block the metastasis of colorectal cancer to distant organs such as liver and lung, significantly weaken the adhesion and invasion ability of colorectal adenocarcinoma cells, reduce the number of organ metastatic nodules, reduce the weight of organs, significantly improve the pathological damage of organ tissues, and has the advantages of high safety, small side effects, good biocompatibility, easy absorption and the like.

The invention discloses oligonucleotide mediating METTL3 variable splicing and application of the oligonucleotide in preparation of a medicine for treating hepatocellular carcinoma. The sequence of the oligonucleotide is any sequence as shown in SEQ ID No.1-7. According to the invention, the expression of the METTL3 splicing isomer is regulated in a targeted manner by using a specific ASO drug, the expression level of the METTL3-A splicing isomer for promoting cancer is reduced, and the expression level of the METTL3-D splicing isomer for inhibiting cancer is increased. The proliferation and clone formation capabilities of hepatoma cells with increased expression of METTL3-D splicing isomers are greatly reduced, and meanwhile, the invasion capability is also remarkably weakened. The expression of the METTL3-D splicing isomer is crucial to the inhibition of liver cancer cells. METTL3 variable splicing regulation provides a new target for clinical treatment of liver cancer, and has a remarkable clinical application prospect. The METTL3-ASO6 and the METTL3-ASO7 can be used for inhibiting the expression of the METTL3-A splicing isomer capable of promoting the cancer in liver cancer cells. The METTL3-ASO6 and the METTL3-ASO7 can be used for inhibiting the proliferation and the clone formation capability of liver cancer cells. The METTL3-ASO6 and the METTL3-ASO7 provided by the invention can be used for efficiently inhibiting the invasion ability of liver cancer cells.

The present invention provides a drug, a pharmaceutical composition, and a combined drug for inhibiting peripheral nerve invasion, and belongs to the field of chemical medicine technology. The present invention has found that ApoD is related to the development of tumor peripheral nerve invasion, and ApoD inhibitors can weaken the migration and invasion ability of tumor cells, thereby inhibiting the progression of peripheral nerve invasion. At the same time, the present invention has found that WP1066 and WZ811 can inhibit the progression of peripheral nerve invasion by inhibiting AopD expression. In addition, the present invention has found that the combined use of WP1066 and WZ811 can play a synergistic role in inhibiting tumor cell peripheral nerve invasion, and can prevent and / or treat tumor recurrence and metastasis, thereby improving patient prognosis and improving quality of life. The present invention provides a basis for clinical drug treatment of patients with peripheral nerve invasion of salivary gland adenoid cystic carcinoma, and has good application prospects.

The present invention provides a marker for auxiliary diagnosis of gastric cancer and its application, belonging to the technical field of tumor treatment. The marker provided by the present invention is the long non-coding RNA (lncRNA) RP11-153K16.2 gene in human peripheral blood exosomes. By detecting its expression level in the peripheral blood of gastric cancer patients by qRT-PCR technology, early and non-invasive diagnosis of gastric cancer can be achieved. The present invention also provides a plasmid gene preparation capable of expressing the lncRNA, which is used to inhibit the proliferation and invasion of gastric cancer cells. Through the application of this gene preparation, it is expected to develop new gastric cancer treatment strategies and improve the survival rate and quality of life of patients.

The application provides an application of a CNOT9 expression inhibitor in preparation of a medicine for preventing, alleviating and / or treating liver cancer. It is found for the first time that the mRNA and protein expression levels of CNOT9 in hepatocellular carcinoma (HCC) tissues are significantly higher than those in paracancerous and normal liver tissues, and the high expression is closely related to the prognosis indexes such as the overall survival and progression-free survival of patients, thereby establishing the value of CNOT9 as a liver cancer diagnosis marker and a new treatment target. Based on this, the application provides an application of a CNOT9 inhibitor in preparation of a medicine for preventing, alleviating and / or treating liver cancer. By down-regulating the expression of CNOT9 through siRNA, the proliferation activity, clonogenicity, migration and invasion ability of liver cancer cells HLF can be effectively inhibited. The application further provides a medicine composition comprising the inhibitor, thereby providing a brand-new target and effective intervention strategy for liver cancer treatment, and having a great clinical development prospect and application value.

This invention relates to the field of biomedical technology, specifically to a micromolecule RNA-19b-3p and its application in the treatment of pancreatic ductal adenocarcinoma. The micromolecule RNA-19b-3p has the nucleotide sequence shown in SEQ ID NO:1. This invention discloses its use in the preparation of a medicament for treating pancreatic ductal adenocarcinoma, achieved by inhibiting the expression and / or activity of the micromolecule RNA-19b-3p. The medicament comprises a substance capable of reducing the expression or activity of the micromolecule RNA-19b-3p. This substance is its inhibitor, suppressor, antagonist, or antisense oligonucleotide. The medicament is used to inhibit the proliferation, migration, and / or invasion of pancreatic ductal adenocarcinoma cells. This invention provides a novel biomarker and therapeutic intervention target for pancreatic ductal adenocarcinoma, clarifies the feasibility of targeted therapy, and possesses clear translational potential.

This invention relates to the field of biomedical technology, specifically to a micromolecule RNA-191-5p and its application in the treatment of pancreatic ductal adenocarcinoma. The micromolecule RNA-191-5p has the nucleotide sequence shown in SEQ ID NO:1. This invention discloses its use in the preparation of a medicament for treating pancreatic ductal adenocarcinoma, achieved by inhibiting the expression and / or activity of the micromolecule RNA-191-5p. The medicament comprises a substance capable of reducing the expression or activity of the micromolecule RNA-191-5p. This substance is its inhibitor, suppressor, antagonist, or antisense oligonucleotide. The medicament is used to inhibit the proliferation, migration, and / or invasion of pancreatic ductal adenocarcinoma cells. This invention provides a novel biomarker and therapeutic intervention target for pancreatic ductal adenocarcinoma, clarifies the feasibility of targeted therapy, and possesses clear translational potential.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a G-protein-coupled receptor 3 (GPR3) or GPR3 downstream signal molecule XPC as a target spot in preparation of a medicine for treating melanoma. The GPR3 is taken as a target spot, and the expression of the GPR3 is knocked out or knocked down, so that the proliferation ability, migration ability and invasion ability of melanoma cells can be remarkably reduced, the Ki67 level can be remarkably reduced, the Cleved-Caspase3 level can be improved, the sensitivity of tumor cells to ultraviolet rays can be improved, the genomes of the tumor cells are damaged, apoptosis occurs, and the melanoma can be treated; the overexpression of the GPR3 promotes the characteristics of tumor stem cells to cause proliferation and metastasis of the tumor cells, and the expression of XPC and a stemness marker can be inhibited and tumor proliferation can be inhibited by knocking out or knocking down the expression of the GPR3. Therefore, GPR3 or a GPR3 downstream signal molecule XPC is an important target spot for treating melanoma.

The invention relates to the technical field of biology, relates to an anti-breast cancer medicine and application, and particularly discloses an anti-breast cancer medicine which comprises an active component, and the active component is a DECR1 inhibitor or a DECR1 binding agent; an application of a DECR1 inhibitor or a DECR1 binding agent in the preparation of a medicament for treating or preventing breast cancer; an application of a DECR1 inhibitor or a DECR1 binding agent in preparation of a drug for improving the sensitivity or treatment effect of an anti-breast cancer drug in treatment or prevention of breast cancer; wherein the DECR1 binding agent is Erigoster B, and the DECR1 binding agent is Erigoster B; according to the application disclosed by the invention, expression of DECR1 in breast cancer tissue cells is inhibited through Erigoster B, so that the proliferation, migration and invasion capabilities of breast cancer are reduced, the ferroptosis probability of breast cancer cells is increased, and a new treatment strategy and thought are provided for breast cancer treatment.